section name header

Pronunciation ⬇

sin-a-KAL-set

Classifications ⬆ ⬇

Therapeutic Classification: hypocalcemics

Pharmacologic Classification: calcimimetic agents

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Increases sensitivity of calcium-sensing receptors located on the surface of chief cells of parathyroid gland to levels of extracellular calcium. This decreases parathyroid hormone (PTH) production with resultant decrease in serum calcium.
Therapeutic effects:
  • Decreased bone turnover and fibrosis.
  • Decreased serum calcium.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration; absorption is enhanced by food and further enhanced by a high-fat meal.

Distribution: Extensively distributed to tissues.

Protein Binding: 93–97%.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4, CYP2D6, and CYP1A2 isoenzymes; 80% excreted in urine as metabolites, 15% in feces.

Half-Life: 30–40 hr.

Time/Action Profile ⬆ ⬇

(effect on PTH concentrations)

ROUTEONSETPEAKDURATION
POrapid2–6 hr6–12 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: ARRHYTHMIA, HF exacerbation, hypotension, QT interval prolongation, TORSADES DE POINTES

F and E: HYPOCALCEMIA

GI: nausea, vomiting

Metab: adynamic bone disease

Neuro: SEIZURES

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis

Parathyroid Carcinoma or Primary Hyperparathyroidism

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Sensipar

Code ⬆

NDC Code